Your browser doesn't support javascript.
SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron.
Tarke, Alison; Coelho, Camila H; Zhang, Zeli; Dan, Jennifer M; Yu, Esther Dawen; Methot, Nils; Bloom, Nathaniel I; Goodwin, Benjamin; Phillips, Elizabeth; Mallal, Simon; Sidney, John; Filaci, Gilberto; Weiskopf, Daniela; da Silva Antunes, Ricardo; Crotty, Shane; Grifoni, Alba; Sette, Alessandro.
  • Tarke A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa 16132, Italy.
  • Coelho CH; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Dan JM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
  • Yu ED; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Methot N; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Bloom NI; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Goodwin B; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Phillips E; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
  • Mallal S; Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
  • Sidney J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Filaci G; Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa 16132, Italy; Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy.
  • Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • da Silva Antunes R; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
  • Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: shane@lji.o
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. Electronic address: agrifoni@lji.org.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA. Electronic address: alex@lji.or
Cell ; 185(5): 847-859.e11, 2022 03 03.
Article in English | MEDLINE | ID: covidwho-1650711
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
We address whether T cell responses induced by different vaccine platforms (mRNA-1273, BNT162b2, Ad26.COV2.S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 variants. T cell responses to early variants were preserved across vaccine platforms. By contrast, significant overall decreases were observed for memory B cells and neutralizing antibodies. In subjects ∼6 months post-vaccination, 90% (CD4+) and 87% (CD8+) of memorycell responses were preserved against variants on average by AIM assay, and 84% (CD4+) and 85% (CD8+) preserved against Omicron. Omicron RBD memory B cell recognition was substantially reduced to 42% compared with other variants. T cell epitope repertoire analysis revealed a median of 11 and 10 spike epitopes recognized by CD4+ and CD8+ T cells, with average preservation > 80% for Omicron. Functional preservation of the majority of T cell responses may play an important role as a second-level defense against diverse variants.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / Memory B Cells / Memory T Cells Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.01.015

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / Memory B Cells / Memory T Cells Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Year: 2022 Document Type: Article Affiliation country: J.cell.2022.01.015